Moderna (NASDAQ: MRNA) is the Cambridge, Massachusetts mRNA platform company whose profile in peptide-news coverage centers on the intismeran autogene (mRNA-4157) individualized neoantigen cancer vaccine program co-developed with Merck. Intismeran encodes up to 34 tumor-specific neoantigen peptides derived from each patient's own tumor mutation signature, delivered by lipid nanoparticle mRNA to train the immune system to attack recurrent disease.
The Phase 3 INTerpath-001 melanoma trial, announced Wednesday August 19, 2026, met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in adults with completely resected Stage IIB-IV melanoma treated with intismeran plus Keytruda (pembrolizumab) versus Keytruda alone. MRNA shares surged approximately 177% in a single session, adding roughly $44.5 billion in market capitalization. The Phase 2b KEYNOTE-942 five-year follow-up presented at ASCO 2026 had shown a 49% reduction in risk of recurrence or death and a 59% reduction in risk of distant metastasis or death versus Keytruda alone. Follow-through analyst forecasts project intismeran sales above $1 billion annually by 2031.
On Thursday August 27, 2026, Moderna announced a $2 billion private placement of convertible senior notes due 2032 to fund the cancer vaccine business and repay existing debt. The company is advancing intismeran in nine total Phase 2 and Phase 3 clinical trials across melanoma, non-small-cell lung cancer, bladder cancer, and renal cell carcinoma. Stories here cover trial readouts, capital raises, manufacturing scale-out, and the broader neoantigen vaccine race with BioNTech, Genentech, and academic peptide-vaccine programs. See #intismeran, #cancer-vaccine, and #keytruda for adjacent threads.
Moderna (NASDAQ: MRNA) announced Friday August 28, 2026 that the UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized its updated Spikevax XFG-adapted COVID-19 mRNA vaccine for adults and children aged six months and older, priced for the autumn NHS vaccination program covering adults 65 and older, care home residents, health and social care workers, and clinically vulnerable groups. For the first time in the UK, the updated Spikevax vaccine will also be available to purchase privately for those not eligible for the NHS Autumn vaccination program, distributed through high street pharmacies, occupational health providers, and private healthcare companies. The authorization mirrors the FDA supplemental BLA approval that Pfizer-BioNTech received Wednesday August 27 for Comirnaty XFG, and lands as the roughly $2 billion August 27 Moderna convertible notes raise gears the company for cancer vaccine expansion.
Moderna (NASDAQ: MRNA) announced Thursday August 27, 2026 a private placement of $2 billion in convertible senior notes due 2032, with proceeds directed to the cancer vaccine business (led by intismeran autogene / mRNA-4157, the individualized neoantigen therapy that encodes up to 34 tumor-specific neoantigen peptides per patient) and to repay existing debt. The raise follows the Wednesday August 19 announcement that the Phase 3 INTerpath-001 melanoma trial of intismeran plus Keytruda met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival, which added roughly $44.5 billion in market cap to MRNA in a single session as shares surged 177%. Moderna is advancing intismeran in nine total Phase 2 and Phase 3 trials across melanoma, NSCLC, bladder cancer, and renal cell carcinoma, and the raise positions the company to accelerate manufacturing scale-out and expansion into new tumor types.
Sell-side analysts published Tuesday August 25, 2026 projections that Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) intismeran autogene (V940 / mRNA-4157) will exceed $1 billion in annual sales by 2031 following the August 19 positive Phase 3 INTerpath-001 melanoma readout. Product context: intismeran autogene is an individualized neoantigen therapy that uses each individual patient's tumor mutation signature to design a personalized mRNA vaccine encoding up to 34 tumor-specific neoantigen peptides. The mRNA is delivered as a lipid nanoparticle injection; cells at the injection site translate the mRNA into the neoantigen peptides, which are then presented to the immune system to generate a targeted T-cell response against the patient's tumor. The INTerpath-001 Phase 3 trial met its primary endpoint of recurrence-free survival and key secondary endpoint of distant metastasis-free survival in adults with completely resected Stage IIB-IV cutaneous melanoma. The $1+ billion 2031 sales trajectory assumes approvals across additional adjuvant indications currently in Phase 3 development including non-small-cell lung cancer (INTerpath-002), renal cell carcinoma (INTerpath-003), and cutaneous squamous cell carcinoma (INTerpath-005). Manufacturing scale-up remains a substantial commercial constraint because each patient dose requires an individualized manufacturing run driven by that patient's tumor sequence, unlike traditional off-the-shelf drugs; Moderna is investing in automated manufacturing infrastructure to support the projected launch volumes. The sales trajectory reset materially resets investor expectations about the personalized neoantigen therapy modality that had traded largely on Phase 2 data until the August 19 confirmatory Phase 3 result.
Merck (NYSE: MRK) and Moderna (NASDAQ: MRNA) announced Wednesday August 19, 2026 that the Phase 3 INTerpath-001 trial of intismeran autogene (V940 / mRNA-4157, an individualized neoantigen therapy) plus pembrolizumab (Keytruda) met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in adults with high-risk (Stage IIB-IV) resected cutaneous melanoma compared to Keytruda alone. Mechanism: intismeran autogene is a personalized mRNA therapy that encodes up to 34 tumor-specific neoantigen peptides selected from the individual patient's tumor mutation signature. The mRNA is delivered as a lipid nanoparticle injection; cells at the injection site translate the mRNA into the neoantigen peptides, which are then presented to the immune system to generate a targeted T-cell response against the patient's tumor. The Phase 3 readout is the first positive Phase 3 for an individualized neoantigen therapy and the first Phase 3 to demonstrate substantial improvement over Keytruda alone in the adjuvant melanoma setting. Trial design: randomized, double-blind, placebo- and active-comparator-controlled global Phase 3 evaluating safety and efficacy of the combination versus Keytruda alone. Phase 2b KEYNOTE-942 five-year follow-up data presented at the 2026 ASCO Annual Meeting had shown a 49% reduction in risk of recurrence or death and a 59% reduction in risk of distant metastasis or death for the combination versus Keytruda alone, and the Phase 3 readout confirms and extends those benefits. The result validates the personalized neoantigen mRNA vaccine platform and opens a substantial commercial pathway for the Merck-Moderna collaboration in adjuvant oncology settings beyond melanoma including non-small-cell lung cancer, renal cell carcinoma, and cutaneous squamous cell carcinoma where INTerpath studies are ongoing.